Evidence map›Paper›PMID 37985993›Full record

ArticleImmunity & ageing : I & A2023

Vascular Cell Adhesion Molecule-1 (VCAM-1) contributes to macular fibrosis in neovascular age-related macular degeneration through modulating macrophage functions.

Wen Deng, Caijiao Yi, Wei Pan, Jian Liu, Jinyan Qi, Juan Chen, Zengchao Zhou, Yiqin Duan, Xiangyan Ning, Jun Li and 3 more

Open access · goldAbstract read
In one paragraph

Article in Immunity & ageing : I & A, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
5.9field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 21 citations in OpenAlex.

  1. The GPX3-VCAM1 Axis Gates Pro-Fibrotic Tubule Cell Fate in Hyperuricemic Nephropathy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Article
  2. Article
  3. Macrophage-Fibroblast Crosstalk Shapes Wound Repair Signaling In Vitro.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026
    Article
  4. Article
  5. Review
  6. Article
  7. The critical role of LRG1 in pathological fibrosis.Journal of molecular medicine (Berlin, Germany) · 2025
    Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Genetic Analysis of Choroideremia-Related Rab Escort Proteins.International journal of molecular sciences · 2025
    Article
  13. Naringin Suppresses CoClAntioxidants (Basel, Switzerland) · 2025
    Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 3 countries.

Wen DengAier School of Ophthalmology, Central South University, Changsha, China.
Caijiao YiAier Institute of Optometry and Vision Science, Changsha, China.
Wei PanAier Institute of Optometry and Vision Science, Changsha, China.
Jian LiuAier Institute of Optometry and Vision Science, Changsha, China.
Jinyan QiAier School of Ophthalmology, Central South University, Changsha, China.
Juan ChenChangsha Aier Eye Hospital, Changsha, China.
Zengchao ZhouChangsha Aier Eye Hospital, Changsha, China.
Yiqin DuanChangsha Aier Eye Hospital, Changsha, China.
Xiangyan NingChangsha Aier Eye Hospital, Changsha, China.
Jun LiChangsha Aier Eye Hospital, Changsha, China.
Changhua YeAier School of Ophthalmology, Central South University, Changsha, China.
Zhongping ChenAier School of Ophthalmology, Central South University, Changsha, China.
Heping XuAier School of Ophthalmology, Central South University, Changsha, China. heping.xu@qub.ac.uk.
He Eye Hospital · CNCentral South University · CNSUNY College of Optometry · US

Funding

Medical Research Council MR/W004682/1
6 · The paper itself

Abstract

backgroundNeovascular age-related macular degeneration (nAMD) is a major cause of blindness in the elderly. The disease is due to the growth of abnormal blood vessels into the macula, leading to the loss of central vision. Intravitreal injection of vascular endothelial growth factor (VEGF) inhibitors (e.g., anti-VEGF) is the standard of care for nAMD. However, nearly 50% of patients do not respond or respond poorly to the therapy. More importantly, up to 70% of nAMD patients develop macular fibrosis after 10 years of anti-VEGF therapy. The underlying mechanism of nAMD-mediated macular fibrosis is unknown although inflammation is known to play an important role in the development of abnormal macular blood vessels and its progression to fibro-vascular membrane. In this study, we measured the intraocular levels of adhesion molecule VCAM-1, ICAM-1, CD44, CD62L, and CD62P in nAMD patients with and without macular fibrosis and investigated the link between the levels of adhesion molecule and clinical features (e.g., visual improvement, retinal thickness, etc.). We further investigated the effect of VCAM-1 in macrophage function in vitro and the development of subretinal fibrosis in vivo using a two-stage laser-induced protocol.

resultsThe aqueous levels of ICAM-1, VCAM-1, CD44, and CD62L were significantly higher in nAMD patients compared to cataract controls. The aqueous level of VCAM-1 (but not other adhesion molecules) was significantly higher in patients with macular fibrosis than those without and the level correlated positively with the retinal thickness. VCAM-1 was highly expressed at the lesion site in the mouse model of subretinal fibrosis. Blocking VCAM-1 or its receptor VLA-4 significantly prevented macrophage infiltration and reduced subretinal fibrosis in vivo. VCAM-1 induced macrophage migration and upregulated the expression of Arg-1, Mmp12 and Il6 but down-regulated the expression of iNOS and Il1b in macrophages.

conclusionsVCAM-1 may contribute to the development of macular fibrosis in nAMD patients by modulating macrophage functions, including migration and profibrotic polarization.

Indexed as

Aqueous humourInflammationMacrophageMacular fibrosisVascular cell adhesion molecule 1

Identifiers

PMID37985993
PMCPMC10659061
OpenAlexW4388828053

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.